Abstract: This disclosure describes a natural language question (NLQ) query service within a service provider network that provides row level security (RLS) for autocomplete during entry of NLQs and fuzzy matching in NLQ answering. The rules take the form of per-user predicates such as Tim can only see rows with region=US. In configurations a complex extraction and preprocessing pipeline to extract distinct combinations of values against RLS predicate “rule keys” is used. Those distinct values are indexed along with grouped rule keys to enable pushing down predicates at auto-complete time. This enables pushing part of RLS rule handling to ingestion time of a dataset rather than handling all RLS rule handling at query time, enabling meeting of latency goals. In configurations, a single logical document of unique cell values is split into multiple documents with a subset of rule keys to handle scalability limits.

Abstract: A syringe adapter includes an outer housing having a sidewall defining an interior space, a membrane housing positioned within the interior space of the outer housing and moveable from a first position within the outer housing to a second position within the outer housing spaced from the first position, with the membrane housing receiving a membrane, a needle hub connected to the outer housing and configured to be connected to a syringe, with the needle hub rotatable relative to the outer housing, and a needle connected to the needle hub. The needle having a first end and a second end positioned opposite the first end, with the second end of the needle received within the membrane when membrane housing is in the first position. The needle is rotatable relative to the needle hub.

Abstract: The present disclosure provides compositions, methods and kits for treatment of pruritus (itch) in an individual. The compositions, methods, and kits are for administering an implant comprising a kappa-opioid receptor agonist to an individual, where the implant comprises a sustained release composition comprising a kappa-opioid receptor agonist and a biocompatible polymeric matrix. Implantation of the device allows a controlled release of kappa-opioid receptor agonist for an extended period of time. The implant may be implanted subcutaneously in an individual in need of continuous treatment with a kappa-opioid receptor agonist for treatment and relief of pruritus.

Abstract: The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.

Abstract: A defect centre-based sensor is disclosed. The sensor comprises instrumentation which includes a generator for causing excitation in an active element, for example a diamond, and a detector for measuring a transition in the active element. The generator is an optical source and/or the detector is an optical detector. The sensor further comprises an optical waveguide and a sensor head in communication with the source and/or the detector via the optical waveguide. The sensor head houses the active element having at least one defect centre, for example, a nitrogen vacancy, responsive to an applied magnetic field, electric field or temperature and a signal delivery arrangement, for example at least one lens, arranged to optically couple the optical waveguide to the active element.

Abstract: Sensor A device is disclosed. The device comprises a magnet (15) arranged to apply an inhomogeneous magnetic field (B) to a given volume (16) and a magnetometer having an active element (8) for sensing magnetic field in a volume which includes the given volume (16).

Abstract: The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.

Abstract: An aqueous personal care composition comprising: one or more amphoacetates; one or more glutamate surfactants selected from sodium lauroyl glutamate, dipotassium cocoyl glutamate, potassium lauryl/myristoyl glutamate and combinations thereof; and cocamide MIPA; wherein the composition is free of sulfates and ethoxylates.

Abstract: The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.

Abstract: A system and method for finding an optimum travel plan for several subsequent destinations. The system can receive several destinations from the user and determine the optimum travel plan. The different destinations can be provided by capturing an address or location from a webpage or uploading an image of the destination.

Abstract: The present application provides processes for the purification of ferric carboxymaltose, the process includes the steps of dissolving crude ferric carboxymaltose in a first solvent; charging the ferric carboxymaltose solution in a reaction vessel with a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.

Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.

Abstract: A defect centre-based sensor is disclosed. The sensor comprises instrumentation which includes a generator for causing excitation in an active element, for example a diamond, and a detector for measuring a transition in the active element. The generator is an optical source and/or the detector is an optical detector. The sensor further comprises an optical waveguide and a sensor head in communication with the source and/or the detector via the optical waveguide. The sensor head houses the active element having at least one defect centre, for example, a nitrogen vacancy, responsive to an applied magnetic field, electric field or temperature and a signal delivery arrangement, for example at least one lens, arranged to optically couple the optical waveguide to the active element.

Abstract: The present invention relates to a disinfection passageway with an alerting system. The passageway includes: a first sidewall; a second sidewall; and a top cover extending between the first sidewall and the second sidewall. The passageway also has a storage tank attached to the outer surface of the first sidewall. The storage tank stores sanitizing liquid for dispensing through a plurality of nozzles on the inner surface of at least one sidewall. A temperature sensor is also attached to the passageway, wherein the temperature sensor is adapted for measuring a body temperature of a user. Finally, a hand sanitizer dispenser on the inner surface of at least one side wall adapted for dispensing hand sanitizer.

Abstract: The present application provides processes for the purification of ferric carboxymaltose, the process includes the steps of dissolving crude ferric carboxymaltose in a first solvent; charging the ferric carboxymaltose solution in a reaction vessel with a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.

Abstract: The present application provides methods for the synthesis of intermediates in the synthesis of Safinamide or a pharmaceutically acceptable salt thereof herein Safinamide Mesylate, that is substantially free of impurities.

Abstract: A system and method for finding an optimum travel plan for several subsequent destinations. The system can receive several destinations from the user and determine the optimum travel plan. The different destinations can be provided by capturing an address or location from a webpage or uploading an image of the destination.

Abstract: Loadable porous structures are disclosed, which are structures with pre-formed pores. The loadable porous structures can be loaded with pharmaceutical substances and optional excipients. The loaded porous structures can then be used as implants, for implantation into a patient for release of pharmaceutical substances over long periods of time. Methods of making and using such structures and implants are also disclosed.

Abstract: An online/electronic platform for hosting images, wherein the online platform can associate the images to the geographical address at which the images are taken and the time at which the images are taken. The disclosed platform provides an interface on an electronic device to upload images to the online platform. The interface may also allow a user to capture the images for uploading to the online platform.

Abstract: The present application generally provides ferric maltol of formula I, and more particularly a crystalline form alfa of Ferric maltol, which is characterized by its PXRD pattern as illustrated herein. Corresponding methods for producing the ferric maltol disclosed herein are also provided.